The FDA has approved Ryzodeg 70/30 (insulin degludec/insulin aspart injection) from Novo Nordisk, to improve blood sugar (glucose) control in...
When treated with once-daily Ryzodeg, from Novo Nordisk, people with type 2 diabetes achieved similar blood sugar control with half...
On 18 October 2012 the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal...
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has unanimously recommended that a cardiovascular outcomes trial should be conducted regarding...
On 18 October 2012, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal...
Data presented at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with Type 2 Diabetes...
Novo Nordisk has announced that the European Commission on 21 January 2013, has granted marketing authorisations for Tresiba (insulin degludec) and...
New analyses demonstrate that Ryzodeg (insulin degludec/insulin aspart), from Novo Nordisk, achieved successful glycaemic control with significantly lower rates of...
Data presented at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms...